Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715706 | 0.82 | SAE1 (0.68) | TP53TSHRSMN1; SMN2 | |
| SCHEMBL16383175 | 0.82 | SLC6A4 (0.69) | SLC6A4IDO1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL104850 | 0.82 | SLC6A4 (0.69) | SLC6A4IDO1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14044082 | 0.81 | SLC6A4 (0.68) | SLC6A4IDO1CYP1A2CYP2D6CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL8170665 | 0.80 | SLC6A4 (0.67) | SLC6A4IDO1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL24324835 | 0.79 | PKM (0.62) | TAAR1ALDH1A1TSHRALOX12SMN1; SMN2 | |
| SCHEMBL2666118 | 0.78 | SLC6A4 (0.64) | SLC6A4IDO1CYP1A2CYP2D6CYP2C19 | |
| Para-Methoxyamphetamine SCHEMBL264634 | 0.78 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL24630912 | 0.78 | SLC6A4 (0.64) | SLC6A4IDO1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL721008 | 0.78 | SLC6A4 (0.64) | SLC6A4IDO1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2020251953-A1 | STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10391070-B2 | Compositions and methods for treating neurological diseases or injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | SLC6A4 3589/4885IDO1 1443/4885CYP1A2 1836/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | SLC6A4 4345/4885IDO1 980/4885CYP1A2 3871/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | SLC6A4 3853/4885IDO1 1824/4885CYP1A2 2366/4885 |
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | SLC6A4 339/4885IDO1 513/4885CYP1A2 118/4885 |
| US-10391070-B2 | Compositions and methods for treating neurological diseases or injury | PROC, GLS, NLN | SLC6A4 2960/4885IDO1 3835/4885CYP1A2 962/4885 |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | SLC6A4 4697/4885IDO1 2001/4885CYP1A2 1156/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | SLC6A4 4345/4885IDO1 980/4885CYP1A2 3871/4885 |
| US-20180185306-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY | PROC, GLS, NLN | SLC6A4 2960/4885IDO1 3835/4885CYP1A2 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.